John Onopchenko

Chief Executive Officer at Endologix, Inc.

John Onopchenko

John Onopchenko

Chief Executive Officer at Endologix, Inc.

Overview
Career Highlights

Endologix, Inc.
Synergy Life Science Partners LLC

RelSci Relationships

3376

Number of Boards

19

Birthday

1959

Age

60

Relationships
RelSci Relationships are individuals John Onopchenko likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at TransEnterix, Inc.

Relationship likelihood: Strong

Co-Founder at TransEnterix, Inc.

Relationship likelihood: Strong

Professional at Synergy Management Company I LLC

Relationship likelihood: Strong

Former Head at Johnson & Johnson Innovation JJDC, Inc.

Relationship likelihood: Strong

Managing Member at Delphi Management Partners VII LLC

Relationship likelihood: Strong

Former Chief Executive Officer at Metronom Health, Inc.

Relationship likelihood: Strong

General Partner at Frazier Management LLC

Relationship likelihood: Strong

Venture Partner at OrbiMed Advisors LLC

Relationship likelihood: Strong

Principal, Venture Investments at Johnson & Johnson Innovation JJDC, Inc.

Relationship likelihood: Strong

Director & Managing Director at SPR Therapeutics LLC

Relationship likelihood: Strong

Paths to John Onopchenko
Potential Connections via
Relationship Science
You
John Onopchenko
Chief Executive Officer at Endologix, Inc.
Education
B.S.

"Ursinus is a remarkable college--student centered, academically rigorous, ambitious, achieving, serious about students in the community--focused, in other words, on the right things."

MBA

The University of Chicago Booth School of Business is a graduate business school located in Chicago, Illinois, at the University of Chicago. Formerly known as the University of Chicago Graduate School of Business, Chicago Booth is the second-oldest business school in the U.S., the first such school to offer an Executive MBA program, and the first to initiate a Ph.D. program in business. The school was renamed in 2008 following a $300 million endowment gift to the school by alumnus David G. Booth. The school has the third-largest endowment of any business school. The school's flagship campus is located in the Hyde Park neighborhood of Chicago on the main campus of the university. The school also maintains additional campuses in London and Asia (originally Singapore, but in July 2013 a move to Hong Kong was announced), as well as in downtown Chicago on the Magnificent Mile. In addition to conducting graduate business programs, the school conducts research in the fields of finance, economics, quantitative marketing research, and accounting. Chicago Booth is currently ranked first in the United States by Bloomberg Businessweek and first globally by the Economist.

Advanced Management Program

Oxford is a collegiate university, consisting of the central University and colleges. The central University is composed of academic departments and research centres, administrative departments, libraries and museums. The 38 colleges are self-governing and financially independent institutions, which are related to the central University in a federal system. There are also six permanent private halls, which were founded by different Christian denominations and which still retain their Christian character.

Memberships
Member
Current

LES has been the leading association for intellectual property, technology, and business development professionals to achieve professional and personal success. Whether you are new to licensing or an experienced licensing executive, LES is your professional home.

Member
Current

National Association of Securities Dealers, the former name of the American self-regulatory organization for broker-dealers, now known as the Financial Industry Regulatory Authority.

Career History
Vice President, Venture Investments
Prior

Johnson & Johnson Development Corp. (JJDC) focuses on in investments in life sciences and technology companies in traditional healthcare sectors including medical devices, diagnostics, pharmaceuticals and consumer products. The firm also invests in emerging healthcare areas including biotechnology and wellness and prevention. JJDC looks for companies with products, services, and technologies that have large addressable markets, clearly-defined competitive advantages and intellectual property protection. They invest in ventures that are backed by an executable clinical and commercialization plan with a clear path to defining and sustaining a leading market position and leveraging competitive advantages to accelerate market adoption and revenue growth.JJDC's investments range from the early stages of seed funding to the advanced stages of series venture management. Investments depend on the stage of funding, phase of product development and alignment of the venture with JJDC's strategic growth objectives and may range from several hundred thousand dollars to millions of dollars. In some advanced stages of funding, the firm will syndicate ventures with other venture capital firms or participate as an investor in a syndicated venture.

Director-Advanced Sterilization Products Division
1996 - 2006

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Director
Prior

Synecor focuses on investments in start-up medical devices and medical technology companies. The firm seeks to create highly-proprietary, disruptive technologies within the largest medical device and combination drug-device markets. Synecor is particularly interested in clinical areas including interventional cardiology, obesity and spine therapeutics

Boards & Committees
Member, Board of Directors
2017 - Current

Endologix, Inc. engages in the research, development, manufacture, and trade of medical devices for the treatment of aortic disorders such as abdominal aortic aneurysms (AAA). Its products include AFX Endovascular AAA System, Nellix and Ovation. The company was founded in March 1992 and is headquartered in Irvine, CA.

Director
Current

Corthera, Inc. develops and manufactures pharmaceuticals, such as cardiovascular preparations. It engages in acquiring, developing, and commercializing therapies for illnesses in the acute care setting. The company was founded in 2003 and is headquartered in San Carlos, CA.

Member, Board of Directors
Current

Synecor focuses on investments in start-up medical devices and medical technology companies. The firm seeks to create highly-proprietary, disruptive technologies within the largest medical device and combination drug-device markets. Synecor is particularly interested in clinical areas including interventional cardiology, obesity and spine therapeutics

Political Donations
$1,000
2012

Honorary Co-Chairman at Pass USMCA Coalition

Transactions
Details Hidden

Endologix, Inc. raised money in a private placement transaction

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by John Onopchenko. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of John Onopchenko's profile does not indicate a business or promotional relationship of any kind between RelSci and John Onopchenko.
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/person/john-onopchenko-3395831
  • https://relationshipscience.com/person/john-onopchenko-3395831